Tylenol use among pregnant women fell after U.S. President Donald Trump linked autism to the over-the-counter pain relief medicine, according to an analysis of U.S. emergency room prescribing patterns published in the UK medical journal Lancet. In September, Trump said pregnant women should avoid using Tylenol, the brand name for the product known as acetaminophen or paracetamol owned by Kenvue. Health officials cited research claiming prenatal Tylenol use is linked with neurodevelopmental disorders to back up his statement. The decrease in Tylenol prescribing appeared to wane after several weeks, possibly in response to messaging from trusted organizations refuting the President's claims, the researchers said. The study led by Dr. Jeremy Faust, a Harvard professor, also found a persistent increase in the use of leucovorin, a form of folinic acid that Trump also touted as a treatment for children with autism during the same press conference. Drug regulators said they would approve the drug based on a U.S. Food and Drug Administration review of patient data. Thousands of women went without